Literature DB >> 7619672

Metabolic disposition of proguanil in extensive and poor metabolisers of S-mephenytoin 4'-hydroxylation recruited from an Indonesian population.

R Setiabudy1, M Kusaka, K Chiba, I Darmansjah, T Ishizaki.   

Abstract

1. The metabolism of proguanil (PG) was studied by measuring PG, cycloguanil (CG) and 4-chlorophenylbiguanide (CPB) in plasma and urine samples after an oral 200 mg dose of PG hydrochloride administered to 14 extensive (EMs) and 10 poor hydroxylators (PMs) of S-mephenytoin of Indonesian origin. 2. The mean ( +/- s.d.) values of the elimination half-life (t 1/2) and AUC of PG were significantly (P < 0.01) greater in the PM than in the EM group (20.6 +/- 3.1 vs 14.6 +/- 3.5 (95% confidence intervals of difference 3.1 to 8.9) h; and 5.43 +/- 1.89 vs 3.68 +/- 0.83 (0.58 to 2.91) micrograms ml-1 h). 3. Plasma concentrations of CG, an active metabolite, could not be detected in all PMs, and those of CPB were sufficiently high to determine a time-course in only four PMs. Mean AUC(0,24 h) values of CPB were significantly (P < 0.05) lower in the PM (n = 4) than in the EM group (n = 14) (0.47 +/- 0.13 vs 0.88 +/- 0.50 (-0.14 to 0.96) micrograms ml-1 h). 4. Log10 percentage urinary recovery of 4'-hydroxymephenytoin correlated significantly (P < 0.05) with the t 1/2 (rs = -0.661) and AUC (rs = -0.652) of PG. 5. PG, CG and CPB were detectable in urine at 12 h in all subjects. Log10 percentage urinary recovery of 4'-hydroxymephenytoin correlated significantly (P < 0.01) with urinary PG/CG (rs = -0.876), PG/CPB (rs = -0.833) and PG/(CG + CPB) (rs = -0.831) metabolic ratios.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7619672      PMCID: PMC1365007          DOI: 10.1111/j.1365-2125.1995.tb04452.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.

Authors:  S A Ward; W M Watkins; E Mberu; J E Saunders; D K Koech; H M Gilles; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

2.  Confidence intervals.

Authors:  C J Bulpitt
Journal:  Lancet       Date:  1987-02-28       Impact factor: 79.321

3.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

Authors:  K Nakamura; F Goto; W A Ray; C B McAllister; E Jacqz; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

4.  Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.

Authors:  T Inaba; M Jurima; M Nakano; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1984-11       Impact factor: 6.875

5.  Comparison of mosquito nets, proguanil hydrochloride, and placebo to prevent malaria.

Authors:  C G Nevill; W M Watkins; J Y Carter; C G Munafu
Journal:  BMJ       Date:  1988-08-06

6.  The activity of proguanil and its metabolites, cycloguanil and p-chlorophenylbiguanide, against Plasmodium falciparum in vitro.

Authors:  W M Watkins; D G Sixsmith; J D Chulay
Journal:  Ann Trop Med Parasitol       Date:  1984-06

7.  Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man.

Authors:  M D Edstein; J R Veenendaal; H V Scott; K H Rieckmann
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

8.  A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil.

Authors:  W M Watkins; J D Chulay; D G Sixsmith; H C Spencer; R E Howells
Journal:  J Pharm Pharmacol       Date:  1987-04       Impact factor: 3.765

9.  Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects.

Authors:  Y Wattanagoon; R B Taylor; R R Moody; N A Ochekpe; S Looareesuwan; N J White
Journal:  Br J Clin Pharmacol       Date:  1987-12       Impact factor: 4.335

10.  Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.

Authors:  P J Wedlund; W S Aslanian; C B McAllister; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

View more
  3 in total

1.  The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.

Authors:  K Na-Bangchang; C Manyando; R Ruengweerayut; D Kioy; M Mulenga; G B Miller; J Konsil
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

2.  Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.

Authors:  Janelle M Hoskins; Gillian M Shenfield; Annette S Gross
Journal:  Eur J Clin Pharmacol       Date:  2003-09-12       Impact factor: 2.953

3.  Estimation of polymorphisms in the drug-metabolizing enzyme, cytochrome P450 2C19 gene in six major ethnicities of Pakistan.

Authors:  Sagheer Ahmed; Saima Gul; Muhammad Akhlaq; Abrar Hussain; Sidrah Tariq Khan; Halimur Rehman; Muhammad Hanif Bangash; Fadwa Al Mughairbi; Muhammad Hamid Hamdard
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.